Document Detail


The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
MedLine Citation:
PMID:  23015095     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Reports about the prognostic value of IDH mutations and the promoter region of the O6-Methyl-guanyl-methyl-transferase gene in secondary high-grade gliomas (sHGG) are few in number. We investigated the prognostic value of IDH mutations and methylation of the promoter region of the MGMT gene in 99 patients with sHGG and analyzed the clinical course of those tumors. Patients with sHGG were screened for IDH mutations by direct sequencing, and, for promoter status of MGMT gene, by the methylation-specific polymerase chain reaction. A total of 48 of 99 patients (48.5 %) had secondary anaplastic gliomas (Group 1), while 51 patients had secondary glioblastomas (Group 2). The median survival time after malignant progression of all patients with sHGG and with an IDH mutation was 4 years, which is significantly longer than in patients with wild-type IDH (1.2 years, p = 0.009). Patients' survival was not significantly influenced by the tumors' MGMT promoter status, both in Group 1- 9.7 years vs. 6.1 years, methylated vs. unmethylated promoter (p = 0.330)-as well as in Group 2-1.5 years vs. 1.6 years, methylated versus unmethylated promoter (p = 0.829). In our population, the IDH mutation status was not associated with increased PFS or median survival time in sGBM patients. However, patients with secondary anaplastic glioma and IDH mutation had a significantly improved outcome. In addition, IDH mutations are a more powerful prognostic marker concerning both PFS and MS than the MGMT promoter status in those patients.
Authors:
T A Juratli; M Kirsch; K Geiger; B Klink; E Leipnitz; T Pinzer; S Soucek; E Schrok; G Schackert; D Krex
Related Documents :
12566285 - Mutations in the ganglioside-induced differentiation-associated protein-1 (gdap1) gene ...
25025995 - Genetic risk of restenosis after percutaneous coronary interventions in the era of drug...
25216705 - The mns16a polymorphism in the tert gene in peri-centenarians from the han chinese popu...
23612575 - Analysis of all subunits, sdha, sdhb, sdhc, sdhd, of the succinate dehydrogenase comple...
17435245 - Multiple trans-sensing interactions affect meiotically heritable epigenetic states at t...
12939655 - Mutation analysis of the cystic fibrosis transmembrane conductance regulator (cftr) gen...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-27
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  -     ISSN:  1573-7373     ISO Abbreviation:  J. Neurooncol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Neurosurgery, University Hospital Carl Gustav Carus, Dresden University of Technology, Fetscherstrasse 74, 01307, Dresden, Germany, tareq.juratli@uniklinikum-dresden.de.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Minimally invasive osteosynthesis of pilon fractures.
Next Document:  Managing the after effects of serious patient safety incidents in the NHS: an online survey study.